Michael Franken M.D.

Michael Franken, M.D. has extensive experience in the biopharmaceutical industry. Michael is currently the Chief Business Officer at EvolveImmune Therapeutics since April 2023. Prior to this, they served as the Founder and President of TEQLA Therapeutics, Inc. since December 2017.

From October 2019 to January 2023, Dr. Franken held the position of Chief Business Officer at LogicBio Therapeutics. In this role, they were responsible for driving the company's business development, strategy, and commercial functions. Michael successfully executed several collaboration and license agreements, including deals with Takeda Pharmaceuticals, Daiichi Sankyo, and CANbridge Pharmaceuticals.

Before joining LogicBio Therapeutics, Dr. Franken founded Red Oak Medicines Inc. in December 2017 and served as the Founder until August 2019. Additionally, they were the EVP and Chief Operating Officer at Artax Biopharma Inc. from January 2016 to December 2017.

Earlier in their career, Dr. Franken held leadership positions at Momenta Pharmaceuticals, Radius Health, Inc., and Genzyme Corporation (now Sanofi). At Momenta Pharmaceuticals, they served as the SVP and President of the Biosimilars Business, overseeing operational management, strategic planning, and P+L responsibility. During this time, they successfully advanced a biosimilar version of Humira to phase 3 and initiated clinical trials for a biosimilar version of Orencia.

At Genzyme Corporation, Dr. Franken held several leadership roles. Michael was the Vice President and General Manager of the Solid Organ Transplant business, responsible for worldwide P+L and achieving revenues of over $260M in 2011. Michael also served as the Vice President of EU/International Transplant, expanding their responsibilities to include all global geographies. Additionally, they served as the Vice President of Immune Mediated Diseases, managing budget and pipeline development for preclinical and early clinical development portfolios.

Dr. Franken began their career at Genzyme Corporation as the Director of Corporate Development. During this time, they played a key role in coordinating corporate initiatives and strategic alliances.

Overall, Dr. Michael Franken's work experience demonstrates their expertise in business development, strategic planning, and commercialization within the biopharmaceutical field.

Michael Franken M.D. received their degree in Medicine from Heidelberg University, where they studied from 1984 to 1991. Michael later pursued further education at the Harvard T.H. Chan School of Public Health, obtaining a Master of Science degree in Health Management and Policy from 1995 to 1997.